High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis

Addiction
Maria Eugenia SociasMichael-John Milloy

Abstract

Cannabis use is common among people on opioid agonist treatment (OAT), causing concern for some care providers. However, there is limited and conflicting evidence on the impact of cannabis use on OAT outcomes. Given the critical role of retention in OAT in reducing opioid-related morbidity and mortality, we aimed to estimate the association of at least daily cannabis use on the likelihood of retention in treatment among people initiating OAT. As a secondary aim we tested the impacts of less frequent cannabis use. Data were drawn from two community-recruited prospective cohorts of people who use illicit drugs (PWUD). Participants were followed for a median of 81 months (interquartile range = 37-130). Vancouver, Canada. This study comprised a total of 820 PWUD (57.8% men, 59.4% of Caucasian ethnicity, 32.2% HIV-positive) initiating OAT between December 1996 and May 2016. The proportion of women was higher among HIV-negative participants, with no other significant differences. The primary outcome was retention in OAT, defined as remaining in OAT (methadone or buprenorphine/naloxone-based) for two consecutive 6-month follow-up periods. The primary explanatory variable was cannabis use (at least daily versus less than daily) during ...Continue Reading

References

Dec 1, 1993·American Journal of Epidemiology·G Maldonado, S Greenland
Aug 26, 1998·JAMA : the Journal of the American Medical Association·S A StrathdeeR S Hogg
Aug 24, 2000·Epidemiology·J M RobinsB Brumback
Feb 28, 2003·The Journal of Pharmacology and Experimental Therapeutics·Diana L Cichewicz, Sandra P Welch
Aug 5, 2008·JAMA : the Journal of the American Medical Association·Evan WoodJulio S G Montaner
Jan 13, 2009·Substance Use & Misuse·Robert Walker
May 16, 2009·The American Journal on Addictions·Wilfrid Noel RabyEdward V Nunes
Nov 27, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Yanhua RenYasmin L Hurd
Aug 24, 2011·Journal of Psychoactive Drugs·Craig ReinarmanTom Heddleston
Mar 27, 2013·Drug and Alcohol Dependence·Kevin P HillRoger D Weiss
Jun 26, 2013·The American Journal on Addictions·Jillian L ScavoneElisabeth J Van Bockstaele
Sep 5, 2013·Current Pharmaceutical Design·Perrine RouxUNKNOWN ANRS Methaville Study Group
Aug 27, 2014·JAMA Internal Medicine·Marcus A BachhuberColleen L Barry
Aug 14, 2015·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Yasmin L HurdDidier Jutras-Aswad
Oct 16, 2015·Journal of Addictive Diseases·Christine TimkoChristina Garrison-Diehn
Oct 21, 2015·Drug and Alcohol Dependence·Crystal J JichaSharon L Walsh
Nov 11, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M-J MilloyJulio Montaner
Mar 24, 2016·The Journal of Pain : Official Journal of the American Pain Society·Kevin F BoehnkeDaniel J Clauw
May 29, 2016·Drug and Alcohol Dependence·Michelle R LofwallSharon L Walsh
Nov 5, 2016·Journal of Clinical Psychopharmacology·Martin A KatzmanLeena Anand
Nov 9, 2016·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·M Eugenia Socías, Keith Ahamad
Dec 30, 2016·MMWR. Morbidity and Mortality Weekly Report·Rose A RuddLawrence Scholl
Mar 23, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Suzanne NielsenBernard Le Foll
Apr 28, 2017·BMJ : British Medical Journal·Luis SordoRoberto Pastor-Barriuso
May 20, 2017·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Joseph K EiblDavid C Marsh
Aug 20, 2017·Harm Reduction Journal·Philippe Lucas
Sep 2, 2017·Cannabis and Cannabinoid Research·Kerstin Iffland, Franjo Grotenhermen
Oct 1, 2017·BMJ : British Medical Journal·M Eugenia Socías, Evan Wood
Oct 12, 2017·American Journal of Public Health·Melvin D LivingstonAlexander C Wagenaar

❮ Previous
Next ❯

Citations

May 22, 2019·The American Journal of Drug and Alcohol Abuse·Joao P De AquinoRobert Rosenheck
Sep 10, 2019·Pain Management·Melissa M GogginGregory C Janis
May 15, 2020·PloS One·Aisling Máire O'ConnorFiona Boland
Dec 29, 2019·Addiction Science & Clinical Practice·Randi SokolZev Schuman-Olivier
Feb 19, 2020·Substance Abuse Treatment, Prevention, and Policy·Guohua Li, Stanford Chihuri
Jan 29, 2021·BMJ : British Medical Journal·Sameer ImtiazJürgen Rehm
Dec 29, 2020·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Philippe LucasZach Walsh
Feb 9, 2021·Exploration of Medicine·Jiayi W CoxLindsay A Farrer
May 4, 2020·Journal of Substance Abuse Treatment·Cecilia L BergeriaKelly E Dunn
Apr 15, 2020·The International Journal on Drug Policy·Jenna VallerianiRyan McNeil
Jun 24, 2020·Peptides·Richard J Bodnar
Feb 13, 2020·The International Journal on Drug Policy·M Eugenia SocíasM-J Milloy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cannabis & Cognition

The effect of cannabis on cognitive functioning is being explored for short and long-term effects. Recent studies have shown conflicting results, with some showing no significant effects and others showing neuropsychological impairment. Discover the latest research on cannabis and cognition here.

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.